The Cancer Letter

Inside information on cancer research and drug development

Clinical Roundup

Phase II trial of Jemperli plus chemotherapy shows positive headline results in patients with metastatic NSCLC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

The PERLA phase II trial met its primary endpoint of objective response rate by Response Evaluation Criteria in Solid Tumors criteria as determined by blinded independent central review. The trial evaluated Jemperli (dostarlimab) in combination with chemotherapy versus pembrolizumab in combination with chemotherapy in first-line patients with metastatic non-squamous NSCLC. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Drugs & Targets

MAIA Biotechnology, BeiGene announce clinical supply agreement

MAIA Biotechnology Inc. and BeiGene entered into a clinical supply agreement to assess the efficacy of THIO, MAIA Biotechnology’s small molecule telomere-targeting anticancer agent, in combination with BeiGene’s immune checkpoint inhibitor tislelizumab, in three cancer indications. The single-arm pivotal phase II trials will study the drug combination in hepatocellular carcinoma, small cell lung cancer, and colorectal cancer.
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account